Summary InflaRx GmbH (InflaRx) is a developer of therapies in the field of acute and chronic inflammation. The company offers development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and certain orhan drug indications.
Its products comprise IFX-1 and IFX-2. The company undertakes various research and development programs in various life science sectors. The company offers antibodies that are able to fulfil requirements determined by InflaRx for generation of suitable drug candidates.
It offers research services through collaboration with universities and biotech companies. InflaRx is headquartered in Jena, Germany.
InflaRx GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
219 pages •
By Asia Market Information & Development Company
• Sep 2020
China’s demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2020 Summary Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 22.214.171.124) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple...
Complement C5 - Pipeline Review, H1 2020 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 34 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes....
Myasthenia Gravis Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H2, 2020" provides an overview of Myasthenia Gravis Clinical trials scenario.This report provides top line data relating to the clinical trials on Myasthenia...
Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2020" provides an overview of Systemic Lupus Erythematosus Clinical trials scenario.This report provides top line data relating to the...
Inflammatory Bowel Disease Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Inflammatory Bowel Disease Global Clinical Trials Review, H2, 2020" provides an overview of Inflammatory Bowel Disease Clinical trials scenario.This report provides top line data relating to the clinical...